LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the ...

Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which ...

Truist Securities expressed confidence in its latest note that Merck will be able to navigate the upcoming Gardasil headwinds ...

We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

President Donald Trump’s Health and Human Services nominee said he will divest his interest in lawsuits against an HPV ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

Merck & Co. Inc. closed 27.25% short of its 52-week high of $134.63, which the company reached on June 25th.

In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.

Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...